Acura Pharmaceuticals Inc. logo Acura Pharmaceuticals (NASDAQ:ACUR) Director Bruce F. Wesson acquired 80,000 shares of the stock on the open market in a transaction dated Friday, May 16th. The stock was purchased at an average cost of $1.13 per share, for a total transaction of $90,400.00. Following the completion of the acquisition, the director now directly owns 94,914 shares of the company’s stock, valued at approximately $107,253. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) weekly performance is -0.81%. On last trading day company shares ended up $1.22. Analysts mean target price for the company is $2.25. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) distance from 50-day simple moving average (SMA50) is -15.51%.
Pfizer Inc. (NYSE:PFE) said Friday that the Food and Drug Administration will let the drug maker apply for approval of its heavily touted experimental breast cancer medicine based on midstage patient testing results. That means New York-based Pfizer won’t have to do bigger, and very expensive, late-stage patient studies to apply for approval of palbociclib, as company executives and investors had hoped. Pfizer Inc. (NYSE:PFE) shares advanced 0.21% in last trading session and ended the day on $29.12. PFE gross Margin is 81.90% and its return on assets is 23.00%.Pfizer Inc. (NYSE:PFE) quarterly performance is -8.02%.
Flexion Therapeutics (NASDAQ:FLXN) posted its quarterly earnings results on Friday. The company reported ($0.86) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.53) by $0.33, Analyst Ratings.Net reports. Flexion Therapeutics Inc. (NASDAQ:FLXN) shares moved down -2.02% in last trading session and was closed at $12.60, while trading in range of $12.51 – $12.86. Flexion Therapeutics Inc. (NASDAQ:FLXN) year to date (YTD) performance is -14.34%.
On May 8, 2014, BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued a press release to announce the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 with the U.S. Securities and Exchange Commission and to provide a review of the Company’s recent achievements and an update on business operations and upcoming milestones for 2014. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) ended the last trading day at $8.69. Company weekly volatility is calculated as 5.10% and price to cash ratio as 17.96.BioDelivery Sciences International, Inc. (NASDAQ:BDSI) showed a positive weekly performance of 3.95%.
In the quarter ending March 31, Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) said its overall group sales fell to 11.496 billion Swiss francs ($13.06 billion), edging out the 11.49 billion francs analysts had forecast. Excluding the currency impact, sales rose 5%. On last trading day company shares ended up $37.72.
Leave a Reply